Proliant’s ImmunoLin Receives GRAS Status

After due consideration of the application, the FDA had no further questions regarding the safety of ImmunoLin as an ingredient in food products.

06/03/09 Proliant Health and Biologicals announced the U.S. Food and Drug Administration granted self-affirmed GRAS status for the company’s proprietary, trademarked ingredient ImmunoLin.

ImmunoLin is the first immunoglobulin concentrate ingredient available to the nutrition industry with GRAS status. After due consideration of the application, the FDA had no further questions regarding the safety of ImmunoLin as an ingredient in food products. The response to the self-affirmation application for ImmunoLin is available at U.S. FDA/CFSAN: Agency Response Letter: GRAS Notice No. GRN 000255.

“The market for food and nutrition products that support gut health and immunity are expanding rapidly,” said Eric Weaver, Chief Scientific Officer at Proliant Health and Biologicals. “The formal approval allows the use of ImmunoLin in products requiring GRAS such as functional foods and beverages, meal replacement and medical foods.”